The effects of nimesulide, a selective inhibitor of cyclooxygenase-2 (COX-2) on azoxymethane (AOM)-induced colon carcinogenesis were investigated in mice. AOM at a dose of 10 mg/kg body wt was administered to male ICR mice once a week for 6 weeks. 
Introduction
Colon neoplasia is currently one of the major causes of death from cancer in all developed countries and thus the search for effective chemopreventive agents has become very important (1) . Epidemiological studies have shown that prolonged use of aspirin is associated with a reduced risk of colorectal cancer (2) . Consistent with these data, several non-steroidal antiinflammatory drugs (NSAIDs) suppressed the development of chemically induced colon carcinomas in rats and intestinal polyps in Min mice with a nonsense mutation of the Apc gene (3) (4) (5) (6) (7) (8) . In addition, clinical trials have demonstrated that one NSAID, sulindac, causes regression of adenomas in patients with familial adenomatous polyposis (9, 10) . Thus, clear benefit has been found with NSAIDs as chemopreventive agents against colon carcinogenesis. However, they also have severe side-effects, causing gastritis, gastric ulcers and gastrointestinal Abbreviations: ACF, aberrant crypt foci; AOM, azoxymethane; COX, cyclooxygenase; NSAIDs, non-steroidal anti-inflammatory drugs.
bleeding, and this is recognized as a serious problem for clinical application.
The target of NSAIDs is cyclooxygenase (COX), the rate limiting enzyme in the conversion of arachidonic acid to prostanoids. Recently, COX was classified into two isoforms, COX-1 and COX-2 (11, 12) . COX-1 is considered as a housekeeping gene and prostanoids synthesized via the COX-1 pathway are responsible for various functions such as protection of the gastric mucosa, vasodilation in the kidney and aggregation of platelets. In contrast, COX-2 is an immediate-early gene, which contributes to pro-inflammatory prostaglandin synthesis. Furthermore, levels of COX-2 mRNA and protein, but not those of COX-1, have been found to be elevated in chemically induced rat colon carcinoma tissues and in human colon carcinomas, when compared with normal mucosa (13) (14) (15) (16) . Thus, COX-2 has been suggested to be involved in inflammation and carcinogenesis. From these observations, the adverse effects of NSAIDs that inhibit both COX-1 and COX-2 (17) might be avoided by selectively targeting COX-2.
Nimesulide (4-nitro-2-phenoxymethanesulfonanilide), a selective inhibitor of COX-2 belonging to the sulfonamide class (18) , is used clinically as an anti-inflammatory drug in several European countries. This compound is a potent anti-inflammatory agent with less ulcerogenic effects than other NSAIDs and severe side-effects have not been recognized (19) (20) (21) (22) . Recently, we have demonstrated that nimesulide suppresses the formation of aberrant crypt foci (ACF), putative precancerous lesions of the colon, induced by a colon carcinogen, azoxymethane (AOM) in rats (23) . Moreover, this COX-2 inhibitor effectively reduced the development of intestinal polyps in Min mice (24) . As part of our search for a safer chemopreventive agent for colon cancer, in the present study we examined the effects of nimesulide on AOM-induced colon carcinogenesis in mice.
Materials and methods

Chemicals
Nimesulide was provided by Helsinn Healthcare SA (Pazzallo-Lugano, Switzerland). AOM was purchased from Sigma (St Louis, MO). Animals Male ICR mice, purchased from Charles River Japan (Atsugi, Japan) at 6 weeks of age, were housed in plastic cages in an air-conditioned room with a 12 h light-dark cycle. Water and basal diet (AIN-76A; Dyets, Bethlehem, PA) or basal diet containing nimesulide were available ad libitum and body weights were measured weekly. Experimental methods A total of 145 male ICR mice, 6 weeks old, were divided into three AOMtreated groups (30 for AOM ϩ basal diet, 40 for AOM ϩ 200 p.p.m. nimesulide and 45 for AOM ϩ 400 p.p.m. nimesulide) and two vehicle groups (10 for saline ϩ basal diet, 20 for saline ϩ 400 p.p.m. nimesulide). The mice received i.p. injections of AOM in sterile saline at a dose of 10 mg/kg body wt or saline only once a week for 6 weeks. The animals in the nimesulidetreated groups were fed the diets containing 200 and 400 p.p.m. nimesulide starting the day before the first carcinogen treatment until the end of the experiment at week 30. Diets containing nimesulide were prepared once a month by mixing with AIN-76A powder diet, and kept at 4°C until use. Fresh diet was provided to the mice once a week. During these processes, dietary nimesulide was confirmed to be stable. Dietary intake for each group was measured every 2 weeks. Thirty weeks after the first carcinogen treatment, all surviving mice were killed. The major organs, including the intestines, were removed and fixed in 10% formalin neutral buffer solution. The number, size and location of all intestinal tumors detectable without a microscope were examined. Intestinal tumor sizes were determined as previously described (25) . All tumors and organs demonstrating apparent abnormalities were embedded in paraffin and sections were stained with hematoxylin and eosin for histological examination.
Statistical analysis
The significance of differences in the incidences of tumors was analyzed by the χ 2 test and other differences by Student's t-test.
Results
Administration of nimesulide in the diet did not affect the feeding and behavior of mice. Based on dietary intake, the daily intake of nimesulide was estimated to be 20.9 and 38.8 mg/kg body wt on average for the 200 and 400 p.p.m. nimesulide-treated groups, respectively. The mean body weights for each group at week 30 were 50.6 Ϯ 1.17 g in the AOM ϩ basal diet group, 49.8 Ϯ 1.05 g in the AOM ϩ 200 p.p.m. nimesulide group, 48.5 Ϯ 0.93 g in the AOM ϩ 400 p.p.m. nimesulide group, 54.0 Ϯ 1.92 g in the saline ϩ basal diet group and 52.9 Ϯ 1.57 g in the saline ϩ 400 p.p.m. nimesulide group. Body weight gain was slightly decreased by the AOM treatment, but no significant differences were observed in the body weights among the groups given the carcinogen. Two animals in the AOM ϩ basal diet group, three animals in the AOM ϩ 200 p.p.m. nimesulide group, five animals in the AOM ϩ 400 p.p.m. nimesulide group and one animal in the saline ϩ 400 p.p.m. nimesulide group died, mostly before week 7. These animals were not included in the effective numbers. Data for the incidences (percentage of mice with cancers), multiplicities (number of cancers per mouse) and sizes of colorectal cancers are summarized in Table I . The incidences were reduced to 32 and 25% by the 200 p.p.m. and 400 p.p.m. nimesulide treatments, respectively, being lower than the 50% for the AOM ϩ basal diet group. No intestinal tumors were found in the groups not receiving AOM. The numbers of colorectal carcinomas per mouse were significantly lower in Moreover, carcinomas Ͼ5 mm diameter were not found in the nimesulide-treated groups. Colorectal carcinomas were located mainly in the distal colon and were not found in the proximal colon. The mean numbers of carcinomas in the middle colon, the distal colon and the rectum were higher in the AOM alone group than in the 200 and 400 p.p.m. nimesulide-treated groups (Figure 1) . Table II summarizes the results of histological examination of AOM-induced colorectal carcinomas. Most were well differentiated or moderately differentiated adenocarcinomas. Signet ring cell and mucinous type carcinomas were rare, being observed in the middle colon and the rectum, respectively. The proportions of histological types did not differ significantly among the groups. When colorectal carcinomas were classified as non-invasive and invasive carcinomas, based on depth of invasion, the mean numbers of both non-invasive and invasive carcinomas per mouse were decreased by treatment with nimesulide.
In addition to colorectal cancers, tumors were also observed in the liver and lung in AOM-treated groups. The incidences of liver tumors were 32% in the AOM ϩ basal diet group, 27% in the AOM ϩ 200 p.p.m. nimesulide group and 30% in the AOM ϩ 400 p.p.m. nimesulide group and no differences were observed among the three groups. The incidences of lung tumors were 29% in the AOM ϩ basal diet group, 35% in the AOM ϩ 200 p.p.m. nimesulide group and 43% in the AOM ϩ 400 p.p.m. nimesulide group. Nimesulide-treated groups tended to show larger lung tumor incidences, but without statistical significance. The majority of these liver and lung tumors were adenomas, with a few adenocarcinomas. In addition, one adenoma was observed in the lung of mouse in the saline ϩ 400 p.p.m. nimesulide group.
Discussion
The present study demonstrates that the COX-2 selective inhibitor nimesulide decreases AOM-induced colorectal carcinomas in ICR mice at concentrations of 200 and 400 p.p.m. in the diet. In contrast, no suppression of tumor development in the liver and lung was noted. We previously reported that nimesulide inhibits AOM-induced ACF formation in the colon of rats (23) and the development of intestinal polyps in Min mice (24) . Thus, nimesulide appears to be an effective chemopreventor of intestinal carcinogenesis.
It is suggested that inhibition of tumors by NSAIDs involves the common property of COX suppression and the resultant reduction in levels of prostaglandins in tissues. Recently, evidence has accumulated suggesting that COX-2 may be a major target of NSAIDs for their chemopreventive effects. COX-2 is inducible by a variety of factors, which include cytokines, growth factors and tumor promoters (12) . Several reports have demonstrated increased COX-2 expression in human and rodent colorectal carcinomas (13) (14) (15) (16) and it has been demonstrated that overexpression of COX-2 may confer a survival advantage on cells by inhibition of apoptosis and a change in cellular adhesion to the extracellular matrix (26, 27) . COX-2 selective inhibitors have therefore become a focus of attention as effective colon cancer chemopreventive agents.
Nimesulide has been clinically used as an anti-inflammatory drug and it shows potent anti-inflammatory, but less ulcerogenic, activity than other NSAIDs in rats (22) . Clinical studies have also provided evidence that nimesulide is better tolerated by the gastrointestinal tract than indomethacin (21) . Consistent with these observations, no gastric abnormalities or other adverse effects of nimesulide were observed in the present long-term carcinogenesis study. Recently, the chemopreventive activity of other COX-2 inhibitors was reported; MF tricyclic reduced the number and size of intestinal polyps in Apc ∆716 knockout mice (28) and celecoxib suppressed AOM-induced colon carcinogenesis in rats (29) . Several other chemicals, including NS-398, Dup 697 and SC-58125, have also been shown to be selective COX-2 inhibitors (30) (31) (32) . Among these, however, only nimesulide has already been employed clinically. Therefore, nimesulide could be a promising candidate in clinical trials to assess the chemopreventive potential against colon cancer in man.
